SCM
PRLD icon

Sterling Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Sterling Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$517 Buy
+97
New +$422 ﹤0.01% 3218
2025
Q2 		– Sell
-227
Closed -$174 – 3361
2025
Q1 		$174 Buy
227
+185
+440% +$173 ﹤0.01% 3100
2024
Q4 		$54 Hold
42
– – ﹤0.01% 3209
2024
Q3 		$87 Buy
+42
New +$195 ﹤0.01% 3203

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Sterling Capital Management's PRLD Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 97 shares worth $517. The stake represents ﹤0.01% of the portfolio and ranks #3218 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in PRLD as recently as Q1 2025.

Sterling Capital Management first reported a position in PRLD in Q3 2024 and has held it in 4 quarters since. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Sterling Capital Management held 97 shares of Prelude Therapeutics worth $517 as of Q2 2026.
  • Prelude Therapeutics was a new Sterling Capital Management position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3218 holding.
  • Sterling Capital Management first reported a position in Prelude Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.